Payment overview · 2025
General Payments
$309.58
11 reported records · 7 companies
Healthcare provider profile · identity verified
Ty Glenn Hargroder, MD
Allopathic & Osteopathic Physicians|Family Medicine|Hospice and Palliative Medicine · EUNICE, LA · NPI 1093761645
Verified facts
What the public records show
CMS Open Payments records show Ty Glenn Hargroder, MD received $309.58 in general payments during 2025 across 11 reported records.
ConvaTec Inc. accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $69.81 | 22.6% | 3 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $66.41 | 21.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.01 | 19.1% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $30.68 | 9.9% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $30.31 | 9.8% | 2 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $29.07 | 9.4% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $24.29 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $309.58 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AFFINITY Normalized: affinity |
Medical Supply | Organogenesis Inc. | $66.41 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $59.01 | 1 | 2025 |
Source payment records
|
|||||
| INNOVAMATRIX AC Normalized: innovamatrix ac |
Device | ConvaTec Inc. | $47.31 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $30.68 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $30.68 | 1 | 2025 |
Source payment records
|
|||||
| 3M Cavilon Normalized: 3m cavilon |
Device | Solventum Corporation | $30.31 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $29.07 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $29.07 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $24.29 | 1 | 2025 |
Source payment records
|
|||||
| AQUACEL FOAM Normalized: aquacel foam |
Device | ConvaTec Inc. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $14.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 448 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 331 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 42 |
| Eliquis | Apixaban | 291 | 32 |
| Gabapentin | Gabapentin | 265 | 31 |
| Trazodone Hcl | Trazodone Hcl | 251 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 243 | 43 |
| Furosemide | Furosemide | 208 | 41 |
| Potassium Chloride | Potassium Chloride | 175 | 37 |
| Losartan Potassium | Losartan Potassium | 160 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 24 |
| Sertraline Hcl | Sertraline Hcl | 141 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 137 | 21 |
| Metformin Hcl | Metformin Hcl | 130 | 21 |
| Memantine Hcl | Memantine Hcl | 129 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 119 | 20 |
| Buspirone Hcl | Buspirone Hcl | 115 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 113 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 112 | 19 |
| Carvedilol | Carvedilol | 111 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 110 | 13 |
| Jardiance | Empagliflozin | 109 | suppressed |
| Xarelto | Rivaroxaban | 109 | suppressed |
| Famotidine | Famotidine | 108 | 18 |
| Risperidone | Risperidone | 104 | 14 |
| Donepezil Hcl | Donepezil Hcl | 103 | 15 |
| Lisinopril | Lisinopril | 103 | 14 |
| Divalproex Sodium | Divalproex Sodium | 100 | 12 |
| Omeprazole | Omeprazole | 99 | 22 |
| Mirtazapine | Mirtazapine | 96 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 15 |
| Levetiracetam | Levetiracetam | 91 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 12 |
| Allopurinol | Allopurinol | 80 | 15 |
| Montelukast Sodium | Montelukast Sodium | 80 | 13 |
| Olanzapine | Olanzapine | 79 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 75 | 53 |
| Tradjenta | Linagliptin | 72 | suppressed |
| Lorazepam | Lorazepam | 70 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 68 | suppressed |
| Linzess | Linaclotide | 68 | 12 |
| Bumetanide | Bumetanide | 67 | suppressed |
| Januvia | Sitagliptin Phosphate | 67 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | suppressed |
| Latanoprost | Latanoprost | 61 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | suppressed |
| Spironolactone | Spironolactone | 58 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | 14 |
| Simvastatin | Simvastatin | 55 | suppressed |
| Alprazolam | Alprazolam | 54 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 14 |
| Sucralfate | Sucralfate | 54 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 54 | suppressed |
| Myrbetriq | Mirabegron | 52 | suppressed |
| Aripiprazole | Aripiprazole | 51 | suppressed |
| Entresto | Sacubitril/Valsartan | 49 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 49 | suppressed |
| Glipizide | Glipizide | 45 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 45 | 13 |
| Bupropion Xl | Bupropion Hcl | 43 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 41 | suppressed |
| Meloxicam | Meloxicam | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | suppressed |
| Trimethoprim | Trimethoprim | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Novolin R | Insulin Regular, Human | 38 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 20 |
| Midodrine Hcl | Midodrine Hcl | 35 | suppressed |
| Calcitriol | Calcitriol | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 34 | 15 |
| Valsartan | Valsartan | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Humulin R | Insulin Regular, Human | 32 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 11 |
| Baclofen | Baclofen | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Rexulti | Brexpiprazole | 29 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 29 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 25 |
| Temazepam | Temazepam | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 21 |
| Rivastigmine | Rivastigmine | 26 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 19 |
| Metolazone | Metolazone | 24 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Timolol Maleate | Timolol Maleate | 23 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 22 | suppressed |
| Ertapenem | Ertapenem Sodium | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 21 | suppressed |
| Restasis | Cyclosporine | 21 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Mesalamine | Mesalamine | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Azathioprine | Azathioprine | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Daptomycin | Daptomycin | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Humira(Cf) Pen | Adalimumab | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Ceftazidime | Ceftazidime | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Felbamate | Felbamate | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Perphenazine | Perphenazine | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $309.58 · 11 records | ConvaTec Inc. | 3M Cavilon, ACTIV.A.C., AFFINITY, AQUACEL FOAM, COLLAGENASE SANTYL, Flexitouch Plus, INNOVAMATRIX AC, Kerecis GraftGuide, Kerecis SurgiClose, Nimbl, OTEZLA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error